How to appeal a Humana lupus & rheumatology denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for lupus & rheumatology

Cited policy: Humana Coverage Policy: Hydroxychloroquine (Plaquenil) for SLE with AAO Retinal Screening Compliance

SLE meeting EULAR/ACR 2019 criteria. Maximum dose ≤5 mg/kg actual body weight/day per AAO 2016/2025. Baseline ophthalmology exam within 1 yr of initiation. Annual screening after 5 yr (or earlier if risk factors: renal disease, tamoxifen, cumulative dose >1000 g) with SD-OCT + 10-2 HVF (24-2 if Asian ancestry per AAO 2025).

How Humana denies lupus & rheumatology — and how to counter it

Where Humana pushes back: 1) Dose exceeds 5 mg/kg threshold; 2) AAO retinal screen not documented; 3) Suspected retinopathy — switch to chloroquine.

Counter-arguments that hold up: AAO 2016 Marmor Ophthalmology + AAO 2025 revision set ≤5 mg/kg actual weight ceiling; risk of retinopathy <1% at 5 yr, <2% at 10 yr, ~20% only after 20 yr cumulative. Submit current SD-OCT + 10-2 HVF (24-2 in Asian patients due to extramacular pattern). EULAR 2023 + KDIGO 2024 + ACR all endorse HCQ for ALL SLE unless absolute contraindication — denying HCQ accelerates flare risk, organ damage accrual, and mortality (HCQ improves 10-yr survival per Ruiz-Irastorza Lupus 2006). Chloroquine has HIGHER ocular toxicity per AAO and is NOT a safer substitute. If suspected retinopathy, dose-reduction or discontinuation is appropriate, not switch to chloroquine.

What Humana typically denies for lupus & rheumatology

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For lupus & rheumatology, expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the lupus & rheumatology treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Benlysta
• Saphnelo
• Lupkynis
• Hydroxychloroquine
• Mycophenolate (MMF)
• Cyclophosphamide IV

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.